Abbott expands CardioMEMS with patient app and dynamic treatment plan
Oct 5, 2026, 9:19 AM EDT1 sourcesAI-analyzed
Why it may matterVerify against the original reporting
Regulatory approval of patient-facing tools can boost device adoption, deepen payer acceptance, and expand the addressable software-enabled services in CardioMEMS, contributing to longer-term revenue growth and improved clinical outcomes. Historical evidence that remote monitoring reduces hospitalizations supports a favorable long-term valuation impulse, though near-term revenue timing remains uncertain.
AI summary
What happened, with direct paths to the underlying reporting
Abbott received FDA approval to update CardioMEMS HF System with CardioGuide HF App and Dynamic Treatment Plan, enabling patient access to pulmonary artery pressure readings. The changes aim to detect worsening heart failure earlier and engage patients between visits, potentially driving higher adoption of CardioMEMS and contributing to improved hospitalization and mortality outcomes over time.
FDA approves CardioMEMS HF updates with patient-facing CardioGuide HF App.
Patients can view PAP readings on smartphones.
Dynamic Treatment Plan enables clinician-set medication adjustments via the app.
Availability planned later this year; adoption may rise.
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.
Related signals
More source-backed signals connected by company or event
Rothschild & Co boosted Abbott Laboratories' price target from 119 to 127 and upgraded the stock to Buy, signaling renewed confidence in ABT's fundamentals. The move follows no st…
Abbott Laboratories agreed to pay more than $384 million to settle DOJ allegations tied to contaminated infant formula. The settlement resolves the lawsuit but signals ongoing reg…
Abbott is FDA De Novo authorized to launch Libre Duo 10 Day, the first dual glucose–ketone biowearable. It monitors glucose and rising ketones in the background, with a US launch…
Abbott announced settlements with three law firms to resolve the Gill case and NEC claims for about 12,700 infants across roughly 1,700 lawsuits, totaling about $670 million. The…
